Phase Ib /II Clinical Trial of Nivolumab Monotherapy and Nivolumab in Combinationwith Ipilimumab in Pediatric Subjects with High Grade Primary CNS Malignancies

Protocol: 
AAAR3302
Phase: 
I/II

Phase Ib /II Clinical Trial of Nivolumab Monotherapy and Nivolumab in Combinationwith Ipilimumab in Pediatric Subjects with High Grade Primary CNS Malignancies

Are you Eligible? (Inclusion Criteria)

a) Prior to study participation, written informed consent from participants, or in the case of minors, written permission (informed consent) from parents, guardians, or legally acceptable representatives must be obtained according to local laws and regulations.
b) Assent from minor participants should be obtained per local laws and regulations and should be documented in accordance with local requirements.
c) Written informed consent and HIPAA authorization (applies to covered entities in the USA only) obtained from the participant/legal representative prior to performing any protocol-related procedures, including screening evaluations
d) Participants must be willing and able to comply with scheduled visits, treatment schedule, laboratory testing, and other requirements of the study, including disease assessment by contrast enhanced MRI.

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States